Search

Your search keyword '"Ngui D"' showing total 2 results
Start Over "Ngui D" Publication Year Range This year
2 results on '"Ngui D"'

1. In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute heart failure.

Author

Arshad MS, Jamil A, Greene SJ, Van Spall HGC, Fonarow GC, Butler J, and Khan MS

Subjects
Humans, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 complications, Acute Disease, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Heart Failure drug therapy, Heart Failure physiopathology, Hospitalization
Abstract

Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiovascular and kidney benefits to patients with heart failure (HF) and/or chronic kidney disease (CKD), regardless of diabetes status and left ventricular ejection fraction (LVEF). Despite robust data demonstrating the efficacy of SGLT-2 inhibitors in both ambulatory and hospital settings, real-world evidence suggests slow and varied adoption of SGLT2 inhibitors among patients hospitalized for HF. Barriers to implementation of SGLT2i may include clinicians' concerns regarding potential adverse events such as diabetic ketoacidosis (DKA), volume depletion, and symptomatic hypoglycemia; or concerns regarding physiologically expected reductions in eGFR. Guidelines lack specific, practical safety data and definitive recommendations regarding in-hospital initiation and continuation of SGLT2i in patients hospitalized with HF. In this review, we discuss the safety of in-hospital SGLT2 inhibitor initiation based on recent trials and highlight the clinical implications of their early use in patients hospitalized for HF., Competing Interests: Declarations. Competing Interests: Dr. Greene has received research support from the Duke University Department of Medicine Chair’s Research Award, American Heart Association, Amgen, AstraZeneca, Boehinger Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards or as consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Corteria Pharmaceuticals, CSL Vifor, Cytokinetics, Eli Lilly, Lexicon, Merck, Novo Nordisk, Otsuka, Roche Diagnostics, Sanofi, scPharmaceuticals, Tricog Health, and Urovant Pharmaceuticals; and has received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Lexicon, and Roche Diagnostics; Dr. Van Spall is funded by the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada, and is a consultant to Bayer and Medtronic; Dr. Fonarow has received research funding from the National Institutes of Health and has received consulting fees from Abbott, Amgen, AstraZeneca, Bayer, CHF Solutions, Edwards Lifesciences, Janssen, Medtronic, Merck, and Novartis; Dr. Butler is consultant to Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Levator, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Roche, Salamandra, Salubris, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vascular Dynamics, Vifor, and Zoll. Dr.Khan has received fees from Bayer; Dr. Arshad and Dr. Jamil have no relevant competing interests to disclose., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Published
2025
Full Text
View/download PDF

2. Unleashing Absorptive Capacity and Unlearning for Organizational Excellence

Author

Abdelkader Mohamed Sghaier Derbali, Shilpa Chaudhary, Rohit Sood, Ajay Chandel, Abdelkader Mohamed Sghaier Derbali, Shilpa Chaudhary, Rohit Sood, and Ajay Chandel

Subjects
Personnel management, Communication in management, Sustainability, Leadership, Organizational behavior, Organizational change
Abstract

'In today's rapidly evolving business landscape, organizations are constantly faced with the challenge of staying competitive and adapting to change. To thrive in this dynamic environment, it is crucial for organizations to develop the capability to learn, unlearn, and relearn effectively. Absorptive capacity, the ability to acquire, assimilate, and apply external knowledge, plays a vital role in fostering innovation, agility, and competitive advantage. By tapping into external sources of knowledge, organizations can leverage new insights, technologies, and best practices to fuel their growth and development. However, absorptive capacity alone is not enough. Organizations must also cultivate the willingness and ability to unlearn outdated knowledge, assumptions, and practices that may hinder progress. Unleashing Absorptive Capacity and Unlearning for Organizational Excellence delves into the interconnected dynamics of absorptive capacity and unlearning within organizational contexts. It emphasizes how absorptive capacity and unlearning can mutually reinforce and amplify each other, creating a positive feedback loop. Covering topics such as continuous improvement, learning cultures, and organizational adaptability, this book empowers leaders, managers, human resources professionals, researchers, academicians, educators, postgraduate students, and more with the knowledge and tools necessary to foster a culture of continuous learning, ultimately contributing to organizational excellence.'--

Published
2025

Catalog

Books, media, physical & digital resources
See catalog results